Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer

Register Now

October 26, 2022 | 7:00 PM ET

Overview

Triple-negative breast cancer (TNBC) is an aggressive, high-grade tumor subtype that is typically diagnosed in women younger than 40 years and leads to higher mortality rates compared with other tumor types. Several disparities, including differences in cancer incidence, mortality and survivorship, and disease-related burden, are associated with TNBC among women of different racial and ethnic groups. Biological, socioeconomic, and geographic social determinants of health have a role in determining the underlying cause of these disparities, emphasizing the need for a holistic approach to analyzing TNBC risk. In addition to these disparities, there are several contributors to treatment inequities for women with TNBC belonging to underserved populations. It is important for members of the multidisciplinary oncology team to recognize the factors that contribute to differences in the development, presentation, and outcomes between women with TNBC and implement appropriate measures to reduce the barriers and inequities experienced by some patients. The oncology health care team should also be educated in culturally competent and responsive care to improve quality of care, communication, and support for cultural minorities seeking treatment for TNBC to best address individual patient needs. The multidisciplinary panelists will discuss potential solutions that can proactively mitigate treatment disparities for patients with TNBC.

Target Audience

Health-system, managed care, oncology, retail, and specialty pharmacists

Learning Objectives

Upon completion of this activity, participants will be able to:

• Explore the ways in which both biological and non-biological factors contribute to disparities in triple-negative breast cancer (TNBC)
• Correlate biological and non-biological disparities with their impact on mortality, quality of life, and survivorship for patients with TNBC
• Apply culturally responsive strategies into practice to improve care equity among patients with TNBC

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta 

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.